Zhaoyan New Drug plans to acquire 100% equity of Yingmao Biotechnology for 830 million yuan

Yingmao Bio is a laboratory laboratory animal breeding and sales company. It is a limited company legally established and validly existing according to Chinese laws. Its main business is the breeding and sales of laboratory laboratory animals. Recently, it was acquired by Zhaoyan New Drug for RMB 830 million, accounting for 100%.

This article is reprinted from: https://www.itjuzi.com/merger/8850
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment